Literature DB >> 6350226

Atenolol for migraine prophylaxis.

B Forssman, C J Lindblad, V Zbornikova.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6350226     DOI： 10.1111/j.1526-4610.1983.hed2304188.x

Source DB:  PubMed          Journal:  Headache        ISSN： 0017-8748            Impact factor:   5.887


× No keyword cloud information.
  15 in total

Review 1.  Pharmacology of antimigraine drugs.

Authors:  P R Saxena; M O Den Boer
Journal:  J Neurol       Date:  1991       Impact factor: 4.849

2.  The pharmacological management of migraine, part 2: preventative therapy.

Authors:  George Demaagd
Journal:  P T       Date:  2008-08

Review 3.  [Alternatives to beta blockers in preventive migraine treatment].

Authors:  S Evers
Journal:  Nervenarzt       Date:  2008-10       Impact factor: 1.214

Review 4.  The prevention of migraine: a critical review with special emphasis on beta-adrenoceptor blockers.

Authors:  V Limmroth; M C Michel
Journal:  Br J Clin Pharmacol       Date:  2001-09       Impact factor: 4.335

Review 5.  Practical approaches to migraine management.

Authors:  Seymour Diamond; Richard Wenzel
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

6.  Preventive pharmacologic treatments for episodic migraine in adults.

Authors:  Tatyana A Shamliyan; Jae-Young Choi; Rema Ramakrishnan; Jennifer Biggs Miller; Shi-Yi Wang; Frederick R Taylor; Robert L Kane
Journal:  J Gen Intern Med       Date:  2013-04-17       Impact factor: 5.128

Review 7.  Current and prospective pharmacological targets in relation to antimigraine action.

Authors:  Suneet Mehrotra; Saurabh Gupta; Kayi Y Chan; Carlos M Villalón; David Centurión; Pramod R Saxena; Antoinette MaassenVanDenBrink
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-07-15       Impact factor: 3.000

8.  [Drug treatment as migraine prophylaxis.].

Authors:  H C Diener; A Ziegler
Journal:  Schmerz       Date:  1989-12       Impact factor: 1.107

Review 9.  Beta-adrenoceptor blockers and calcium antagonists in the prophylaxis and treatment of migraine.

Authors:  K E Andersson; E Vinge
Journal:  Drugs       Date:  1990-03       Impact factor: 9.546

10.  Optimizing prophylactic treatment of migraine: Subtypes and patient matching.

Authors:  Michel Dib
Journal:  Ther Clin Risk Manag       Date:  2008-10       Impact factor: 2.423
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.